CCA
KLDO

Catalyst Capital Advisors’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Catalyst Capital Advisors’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-493
Closed -$7K – 494
2019
Q1 		$7K Buy
+493
New +$6.79K ﹤0.01% 339

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Catalyst Capital Advisors's KLDO Position: Q2 2019 in Review

Catalyst Capital Advisors sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2019, closing a stake of 493 shares — an estimated $7K sold.

Catalyst Capital Advisors first reported a position in KLDO in Q1 2019 and held it in 1 quarter. The position peaked at $7K in Q1 2019. 37 funds tracked by Wall St. Rank hold KLDO as of Q2 2019.

  • Catalyst Capital Advisors reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 493 Kaleido Biosciences, Inc. Common Stock shares in Q2 2019, an estimated $7K.
  • Catalyst Capital Advisors first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's Kaleido Biosciences, Inc. Common Stock position peaked at $7K in Q1 2019.
  • 37 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2019.

Based on Catalyst Capital Advisors's 13F filing for Q2 2019, filed 8 Aug 2019.